Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 30
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
646
-12.71%
|
$323,000
$500.0 P/Share
|
|
Aug 30
2024
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
646
+11.28%
|
$98,192
$152.74 P/Share
|
|
Aug 30
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,784
-27.46%
|
$1,888,216
$499.0 P/Share
|
|
Aug 08
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
1,292
-22.56%
|
$602,072
$466.29 P/Share
|
|
Aug 08
2024
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,292
+18.41%
|
$196,384
$152.74 P/Share
|
|
Aug 07
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-8.93%
|
$1,085,280
$476.75 P/Share
|
|
Aug 01
2024
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
5,295
-11.69%
|
$2,689,860
$508.0 P/Share
|
|
Aug 01
2024
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,295
+10.47%
|
$661,875
$125.71 P/Share
|
|
Jul 30
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-14.32%
|
$7,677,010
$505.0 P/Share
|
|
Jul 24
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-8.2%
|
$1,112,640
$488.46 P/Share
|
|
Jul 22
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-12.52%
|
$7,555,394
$497.0 P/Share
|
|
Jul 10
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-7.58%
|
$1,110,360
$487.34 P/Share
|
|
Jun 26
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-7.04%
|
$1,073,880
$471.72 P/Share
|
|
Jun 12
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-6.58%
|
$1,089,840
$478.0 P/Share
|
|
Jun 12
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
7,288
-31.33%
|
$3,483,664
$478.0 P/Share
|
|
Jun 11
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,824
-22.68%
|
$3,282,344
$481.96 P/Share
|
|
Jun 05
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Bona fide gift
|
Indirect |
4,600
-100.0%
|
-
|
|
Jun 03
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,250
-6.45%
|
$1,495,000
$460.0 P/Share
|
|
Jun 03
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,175
-4.24%
|
$1,000,500
$460.0 P/Share
|
|
May 31
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,250
-4.2%
|
$1,001,250
$445.0 P/Share
|
|
May 30
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,350
-4.21%
|
$1,031,650
$439.11 P/Share
|
|
May 29
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-6.17%
|
$1,014,600
$445.56 P/Share
|
|
May 28
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,250
-6.06%
|
$1,475,500
$454.79 P/Share
|
|
May 24
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
1,565
-1.27%
|
$715,205
$457.0 P/Share
|
|
May 24
2024
|
Reshma Kewalramani CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
1,565
+1.26%
|
$292,655
$187.53 P/Share
|
|
May 22
2024
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
7,073
-15.03%
|
$3,168,704
$448.0 P/Share
|
|
May 22
2024
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,073
+13.06%
|
$657,789
$93.51 P/Share
|
|
May 20
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-11.13%
|
$6,795,294
$447.0 P/Share
|
|
May 15
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
69
-0.14%
|
$29,670
$430.93 P/Share
|
|
May 15
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
32
-0.06%
|
$13,760
$430.93 P/Share
|
|
May 15
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
54
-0.21%
|
$23,220
$430.93 P/Share
|
|
May 15
2024
|
Jennifer Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
922
+50.0%
|
-
|
|
May 14
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
14,112
+31.93%
|
-
|
|
May 02
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
467
-9.53%
|
$187,734
$402.95 P/Share
|
|
May 01
2024
|
Suketu Upadhyay Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,168
-31.34%
|
-
|
|
May 01
2024
|
Suketu Upadhyay Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+21.17%
|
-
|
|
May 01
2024
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
501
+23.43%
|
-
|
|
May 01
2024
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,168
-32.41%
|
-
|
|
May 01
2024
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+21.74%
|
-
|
|
May 01
2024
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+16.96%
|
-
|
|
May 01
2024
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+13.67%
|
-
|
|
Apr 02
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
240
-3.1%
|
$100,560
$419.0 P/Share
|
|
Apr 01
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-2.82%
|
$94,050
$418.1 P/Share
|
|
Feb 26
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
3,004
-5.15%
|
$1,276,700
$425.7 P/Share
|
|
Feb 26
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
354
-0.63%
|
$150,450
$425.7 P/Share
|
|
Feb 26
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
883
-5.24%
|
$375,275
$425.7 P/Share
|
|
Feb 26
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,034
-9.2%
|
$2,139,450
$425.7 P/Share
|
|
Feb 26
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
883
-9.98%
|
$375,275
$425.7 P/Share
|
|
Feb 26
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,239
-14.11%
|
$1,801,575
$425.7 P/Share
|
|
Feb 23
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,309
-5.82%
|
$1,426,179
$431.79 P/Share
|